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A B S T R A C T   
Background: Tick-borne encephalitis (TBE) is increasing in Europe. We aimed to evaluate the immunogenicity 
and safety of TBE-vaccination. 
Methods: This systematic review was registered at PROSPERO (#CRD42020155737) and conducted in accor-
dance with PRISMA guidelines. We searched CINAHL, Cochrane, Embase, PubMed, and Scopus using specific 
terms. Original articles, case reports and research abstracts in English, French, German and Italian were included 
for screening and extracting (JER; PS). 
Results: Of a total of 2464 records, 49 original research publications were evaluated for immunogenicity and 
safety. TBE-vaccines showed adequate immunogenicity, good safety and interchangeability in adults and chil-
dren with some differences in long-term protection (Seropositivity in 90.6–100% after primary vaccination; 
84.9%–99.4% at 5 year follow up). Primary conventional vaccination schedule (days 0, 28, and 300) demon-
strated the best immunogenic results (99–100% of seropositivity). Mixed brand primary vaccination presented 
adequate safety and immunogenicity with some exceptions. After booster follow-ups, accelerated conventional 
and rapid vaccination schedules were shown to be comparable in terms of immunogenicity and safety. First 
booster vaccinations five years after primary vaccination were protective in adults aged <50 years, leading to 
protective antibody levels from at least 5 years up to 10 years after booster vaccination. In older vaccinees, > 50 
years, lower protective antibody titers were found. Allergic individuals showed an adequate response and 
immunosuppressed individuals a diminished response to TBE-vaccination. 
Conclusions: The TBE-vaccination is generally safe with rare serious adverse events. Schedules should, if possible, 
use the same vaccine brand (non-mixed). TBE-vaccines are immunogenic in terms of antibody response but less 
so when vaccination is started after the age of 50 years. Age at priming is a key factor in the duration of 
protection.   
1. Introduction 
Being endemic in 27 European countries with around 5′000–10′000 
notified cases annually, tick-borne encephalitis (TBE) is one of the most 
important causes of viral encephalitis and the most frequent cause of 
viral meningitis in Europe [1–3]. TBE is geographically focused in 
Central and Eastern Europe, the Baltic States, the Russian Federation, 
and Japan, trending towards both an expansion of risk areas and an 
increase in incidence [2–7]. In Switzerland, incidence of TBE has 
increased significantly in the last few years, with more than 350 cases 
recorded in 2018 [8]. 
TBE is caused by the human pathogenic TBE virus, which is a 
member of the Flaviviridae family [3,4,9,10]. Three subtypes based on 
geographic origin and antigenic characteristics are of human impor-
tance: Far-Eastern, Siberian, and European [4,11]. Most European TBE 
cases are tick-transmitted by the ticks Ixodes ricinus with more than 100 
species of wild and domestic animals acting as hosts reservoir [9,12,13]. 
Additionally, in certain areas TBE cases are transmitted from ingesting 
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unpasteurized milk or milk products of infected animals the so-called 
“alimentary TBE” and by Dermacentor reticulatus ricks respectively [10, 
14]. 
The disease TBE is reported more frequent in males [15]. In children 
the disease is milder [16]. Adults typically show a biphasic course: 
during the approximately one week long viremic phase, influenza-like 
symptoms (fever, fatigue, myalgia, and headache) occur [2,9,17]. 
Thereafter, most infected cases recover but around 5–15% develop a 
broad spectrum of neurological symptoms (ranging from mild menin-
gitis to severe meningoencephalomyelitis) [8,9,17]. Long-term neuro-
logical sequelae are described frequently and 0.5–2% of all TBE cases 
were reported to be fatal [2,9,18–20]. 
No antiviral treatment against TBE exists [3,21,22]. Active vacci-
nation is a practical preventive measure to reduce case numbers [10, 
21–23]. There are two inactivated virus vaccines licensed in Europe: 
FSME-Immun® (Pfizer), in some countries distributed as Ticovac®, and 
Encepur® (Bavarian Nordic) [24]. FSME-Immun® is based on the TBE 
virus strain Neudoerfl (Nd), whereas Encepur® is based on the TBE virus 
strain Karlsruhe-23 (K23) [18]. Both vaccines have a pediatric TBE 
vaccine variant [18]. 
To describe a vaccine’s potential to prevent an infection, the two 
terms efficacy and effectiveness are used. While efficacy describes the 
effect measured in clinical trials (i.e. under ideal circumstances), effec-
tiveness represents the results based on an epidemiological investigation 
under real world circumstances [25]. For the European TBE vaccines an 
effectiveness of 95–99% has been calculated in Austrian field studies [2, 
24]. To measure the immunogenicity specific TBE antibodies are eval-
uated using different laboratory test methods as listed in Box 1. The 
neutralization test (NT) is the most reliable to compare the TBE--
vaccines’ immunogenicity [26,27]. These antibodies show an age de-
pendency with decreasing levels in elderly while keeping the same 
avidity. This immune aging process is termed immunosenescence [3,9]. 
2. Aim 
Using a systematic review, we aimed to evaluate safety and 
immunogenicity of TBE-vaccination. 
3. Methods 
We systematically reviewed original research papers addressing 
European TBE-vaccines’ immunogenicity and safety in accordance with 
PRISMA guidelines [28]. The systematic review was registered at 
PROSPERO: #CRD42020155737. 
3.1. Study eligibility and search strategy 
To identify appropriate studies, the following international data-
bases were systematically searched with specific search terms as shown 
in Appendix 1: CINAHL, Cochrane, Embase, PubMed, and Scopus. In-
clusion criteria were papers in English, French, German or Italian lan-
guage, published in the period from January 1st, 2009, to August 31st, 
2019, and being original articles, case reports or research abstracts. A 
Cochrane systematic review, published in 2009, summarizes important 
earlier findings, therefore, we decided not to include studies published 
earlier than 2009 [17]. Exclusion criteria were papers in other languages 
than the above mentioned and animal studies. 
3.2. Data extraction 
An evidence-table was created in Microsoft Word to extract the 
relevant data of original research (including population, intervention, 
control group, outcomes (PICO), study type, vaccines, laboratory anal-
ysis). To assess the methodological quality of the studies selected, we 
analyzed the strength of each study (original research and published 
abstracts) as displayed in Appendix 2. 
3.3. Statistical analysis 
Results of immunogenicity and safety for the TBE vaccines were 
investigated by two researchers (JER, PS) to conclude evidence-based 
recommendations in a narrative form. Different available laboratory 
Box 1 
Laboratory tests to measure anti-TBE-antibodies  
Laboratory tests 
NT – Neutralization Test [26,27] 
Serum sample or dilution of antibodies is mixed 
with a viral suspen- sion on top of host cells. 
Reaction of antibodies lead to antibody- mediated 
neutralization of the virus and protection of the 
host cells. Dilution of the sera leads to a minimum- 
protective concentration: a titer ≥ 1:10 is assumed 
to be protective. 
ELISA – Enzyme-Linked Immunosorbent Assay 
[77,78] 
Serum sample or dilution of antibodies is mixed 
onto an assay with antibody binding sites. If 
binding takes place an enzyme mediated reaction 
takes place which can be recorded. An approach to 
standard- ise the results is to present them in 
Vienna international units/ml (VIEU/ml), whereas 
1000 VIEU/ml were assigned to a standard serum.    
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tests are used to quantify a vaccine’s immunogenicity but this leads to 
difficulties in comparing study results. Therefore, in this systematic re-
view a study’s laboratory test methodology is labeled in Table 1 and 
Table 2. If available, the results acquired by an NT were used for 
interpretation. 
4. Results 
After removing duplicates and screening, 55 papers were selected for 
full-text assessment from the investigated databases. Three additional 
publications were identified for full-text assessment through checking 
the included papers’ reference lists. Title-, abstract-, and full-text 
screening was conducted by two researchers (JER, PS). Of the 58 full- 
text assessed papers, 49 publications (40 pieces of original articles, 
five research abstracts of poster/oral sessions, three case reports and one 
case series) were investigated for immunogenicity and safety. Of the 40 
original abstracts 26 showed external funding and/or sourcing, 
including 20 with connections to vaccine companies. Relevant data of 
published original articles were included into two comprehensive tables 
(Tables 1 and 2), while data from research abstracts and case reports/ 
series were presented in a narrative form only. Nine studies were 
excluded for qualitative analysis after full-text assessment and were used 
for background information if relevant: Three systematic reviews were 
found and were considered for background discussion [13,17,29]. A 
further five reviews/expert opinions and one original article did not 
include relevant information for our analysis [3,11,30–33]. A PRISMA 
flow diagram (Fig. 1) demonstrates the selection process. 
4.1. Immunogenicity (Table 1) 
37 investigated original articles reported immunogenicity data. Fully 
vaccinated individuals regardless of the route of vaccination or delays in 
booster intervals were found to have an adequate immune response [10, 
18,21,34–40]. Data on primary vaccination schedules are displayed in 
Table 3. Furthermore, the European licensed vaccine FSME-Immun also 
showed cross protection against Far Eastern and Siberian TBEV strain 
subtypes [4]. In adults with allergies compared to vaccinees with no 
allergies, higher antibody levels were found after TBE-vaccination [22]. 
High levels of protective antibodies do not guarantee prevention of TBE 
[41]. Vaccine failure numbers were low and were associated with a 
more severe illness, occurring more often in elderly [2,42,43]. Detailed 
data on immunogenicity are shown in Table 1. 
The elderly have lower antibody levels with a diminishing immune 
response starting in individuals aged >60 years and even in individuals 
aged ≥50 years [9,22,44]. Most investigated vaccine failures occurred in 
individuals aged ≥50 years but failures also occurred in younger in-
dividuals [2,45]. Further, individuals ≥60 years with an extra priming 
dose reported no TBE-vaccine failure [2]. 
In children, aged 1–15 years, the vaccine formulas of Encepur® and 
FSME-Immun® lead to high immunogenicity after primary vaccination 
of 95.6% up to 100% and high long-term seropositivity up to 5 years 
after primary vaccination [16,19,36,46–48]. There seems to be no 
age-related differences in the avidity and functional activity of anti-
bodies induced by vaccination [2,49]. 
4.1.1. Booster-interval 
In children, long term seropositivity for vaccine Encepur® Children 
and FSME-Immun® Junior were reported for up to 5 years, or 10 years, 
respectively after primary vaccination [38,50]. In adults both primary 
vaccination with Encepur® or FSME-Immun® lead to high long term 
seropositivity (77.3%–94% at ten year follow-up; 91.8% at a median of 
15 year of follow-up) [10,22,44,51,52]. However, age groups >60 years 
showed a faster decline in seropositivity levels [38,44,53]. 
4.1.2. Interchangeability of TBE vaccines 
For both adults and children TBE vaccines can be largely inter-
changed for primary and booster vaccination [18,37,38,46]. However, 
one study demonstrated a faster decrease in seropositivity in children 
receiving a mixed primary vaccination schedule (two doses of 
FSME-Immun® Junior followed by one dose Encepur® Children) [16]. 
4.1.3. Special groups 
Seropositivity was found to be lower in 66 immunosuppressed pa-
tients compared to healthy individuals at 13 months follow-up after 
primary vaccination schedule [54]. In 17 thymectomized patients no 
significant differences in antibody levels compared to healthy controls 
was presented [55]. We found no papers on TBE vaccination in pregnant 
women. Allergic individuals with or without specific immunotherapy 
showed adequate immunogenicity [56]. Furthermore, Hepatitis-B vac-
cine failure showed no correlation to TBE-vaccine failure, as patients 
with Hepatitis-B vaccine failure were able to gain adequate TBE-vaccine 
immunogenicity [1]. We found no gender specific data on 
immunogenicity. 




Evidence-table of original research investigation on TBE vaccine safety.  
Author, Year doi:1): (#) Study Type Original Study Title 
Funding & Sourcing 
Vaccine(s) Antibody methodology 
Measure of seropositivity 
Outcome: 
Safety 
Loew-Baselli et al. [38] 2009 
https://doi.org/ 
10.4161/hv.5.8.8571 
open label, phase IV, multi- 
center, follow-up study 
Seropersistence of tick-borne encephalitis antibodies, 
safety and booster response to FSME-Immun® 0.5 ml 
in adults aged 18-67 years 




Neutralization Test titers 
≥1:10 
Safety assessed in 328 individuals 
FSME-Immun® booster reactions: 
SAE2) n (%) 0/328 (0%) 
LR2) n (%) 22/328 (6.7%) 
SR2) n (%) 2/328 (0.6%) 
fever n (%) 0/328 (0%) 






single blind study 
Antibody response following administration of two 
paediatric tick-borne encephalitis vaccines using two 
different vaccination schedules 





Neutralization Test titers 
≥1:10 
334 children assessed for safety 
Pain at the injection site (%) of all (n) 
1st dose E.C.3) ≤ 36% of 117 
2nd dose E.C.3) ≤ 26% of 116 
1st dose F-I.J.3) ≤ 31% of 120 
2nd dose F-I.J.3) ≤ 31% of 118 
Fever > 39◦C after 
1st dose all vaccines 1.8% of 334 
2nd dose all vaccines 0.9% of 331 
Serious adverse events: 0% of 334 





multi-centre dose finding 
study 
Clinical evaluation to determine the appropriate 
paediatric formulation of a tick-borne encephalitis 
vaccine 
Funding & sourcing:  
- Baxter 
FSME-Immun®4) ELISA >126 VIEU/ml Safety analysis in 2417 children 
1-5 years of age n (%) 
Restlessness 53/584 (9.1%) 
6 – 15 years of age (n) 
fatigue 102/1833 (5.6%) 
Malaise 76/1833 (4.2%) 
1 – 15 years of age n (%) 
Injection site pain 272/2417 (11.3%) 
Tenderness 438/2417 (18.1%) 
Nausea 76/2417 (3.1%) 
serious AE 0/2417 (0%) 
fever at 1stdose5) 230/2374 (9.7%) 
Fever in age group n (%) 
1-2 years 66/183 (36.1%) 
3-6 years 72/559 (12.9%) 
7-15 years 92/1540 (5.4%) 
total (1-15 years) 230/2374 (9.7%) 






multi center, phase III 
comparison study 
Comparison of immunogenicity and safety between 
two paediatric TBE vaccines 





Neutralization Test titers 
≥1:10 
Safety assessed in 302 individuals6 
injection site reactions first vaccination 
FSME-IJ 6) 19/150 (12.7%) 
Ence. C. 6) 44/152 (28.9%) 
injection site reactions second vaccination 
FSME-IJ 6) 13/150 (8.7%) 
Ence. C. 6) 34/152 (22.4%) 
Fever after first | second vaccination 
FSME-IJ6) 12/150 (8%) |2/149 (2.0%) 
Ence. C. 6) 14/152 (9.2%)|7/152 
(4.6%) 
SAE6) 0/203 (0%) 
Schumacher et al. [59] 2010 
https://doi.org/10.1016/j. 
vaccine.2010.04.002 
retrospective data analysis of 
Swiss data bases7) 
Surveillance for adverse events following 
immunization (AEFI) in Switzerland–1991-2001 
Funding & sourcing:  
- Federal Office of Public Health 
Switzerland 
unspecified N/A 73 reported TBE-vaccine adverse events between 1991 – 
2001 were investigated.8) 
Mild adverse events n=4/73 (5.5%) 
SAE n=19/73 (26%) 
Allergic reactions n=3/73 (4.1%) 
Local reactions n=0/73 (0%) 
Systemic reactions n=42/73 (57.5%) 
(continued on next page) 
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Table 2 (continued ) 
Author, Year doi:1): (#) Study Type Original Study Title 
Funding & Sourcing 
Vaccine(s) Antibody methodology 
Measure of seropositivity 
Outcome: 
Safety 
Mad’ar et al. [82] 2011 
https://doi.org/10.21101/ 
cejph.a3634 
retrospective data analysis of 
diabetic patients 
Vaccination of patients with diabetes mellitus – a 
retrospective study 
Funding & sourcing:  
- Avenier Inc. 
FSME-Immun® 
Encepur® 
N/A TBE-vaccination was performed using Encepur® (n=6) and 
FSME-Immun® (n=223) without increasing the risk of 
serious adverse events. 




booster vaccine study 
Immunogenicity of delayed TBE-vaccine booster 
Funding & sourcing:  
- Baxter 
- Center for Clinical Research in Sweden 
-Crucell 
-Novartis 
FSME-Immun® Neutralization Test titers 
of ED50 (50% effective 
dose) ≥5 
Total of 260 individuals assessed for safety. 
AE9) at injection site pain: n=22/260 
tenderness: n=25/260 
mild AE9): n=25/260 (10%) 
SAE9) events: n=0/260 (0%) 






phase III protectivity study 
Antibody persistence after two vaccinations with 
either FSME-IMMUN® Junior or ENCEPUR® 
Children followed by third vaccination with FSME- 
IMMUN® Junior 






Neutralization Test titers 
≥1:10 
298 children were assessed for adverse events10) 
systemic 
reactions 
1-2y 3-6y 7-11y 
fever 1.0% 4.0% 11.1% 
local 
reactions 




2.0% 17.0% 30.3% 




booster follow-up study Factors associated with seroimmunity against tick borne 
encephalitis virus 10 years after booster vaccination 
Funding & sourcing: 
-Novartis 
-Baxter 
FSME-Immun® Neutralization Test titers 
≥1:10 
In adults suffering of allergies (including atopy and 
anaphylactic allergies) significant higher antibody levels 
were found compared to individuals without allergy. 






Five-year follow-up after a first booster vaccination 
against tick-borne encephalitis following different 
primary vaccination schedules demonstrates long-term 
antibody persistence and safety 
Funding & sourcing: 
- Novartis Vaccines 
Encepur® Neutralization Test titers 
≥1:10 
278 adults were analyzed for adverse events. 
pain 55% swelling 6% 
erythema 8%   
Systemic solicited reactions: 30% 
myalgia 17% malaise 7% 
headache 14% nausea 4% 
arthralgia 5% fever 1% 
SAE11) 5% SAE11) 





booster cohort study 
Analysis of delayed TBE-vaccine booster after primary 
vaccination 
Funding & sourcing:  
- Virion/Serion GmbH  
- Robert Koch Institute 
FSME-Immun® Neutralization Test titers 
≥1:10 
Total of 88 individuals were analyzed for safety 
Total adverse events n=7/88 (8%) 
Mild adverse events n=2/88 (2.3%) 
Systemic reactions n=5/88 (5.7%) 
Fever and/or malaise n=2/88 (2.3%) 






Tick-borne encephalitis (TBE) vaccine to medically 
immunosuppressed patients with rheumatoid arthritis: A 
prospective, open label multi-centre study 
Funding & sourcing:  
- Abbott  
- Novartis  
- Crucell  
- GlaxoSmithKline  




Neutralization Test titers 
of ED50 (50% effective 
dose) ≥5 
Safety investigation included 122 individuals. One 
immunosuppressed individual suffered of gastroenteritis 
two days after first dose vaccination. There were no Serious 
adverse drug reactions reported. 




administration route study 
Comparable immune responsiveness but increased 
reactogenicity after subcutaneous versus intramuscular 
administration of tick-borne encephalitis (TBE) vaccine 
Funding & sourcing:  
- Pfizer Vaccines 
FSME-Immun® Neutralization Test titers 116 adults were assessed for safety analysis12) 
local reactogenicity (SC / IM) 
n=54/58 (93.2%) / n=29/58 (50%) 
local pain (SC / IM) 
n=44/58 (75.9%) / n=26/58 (44.8%) 
fever (SC / IM) 
n=0/58 (0%) / n=2/58 (3.4%) 
(continued on next page) 
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Table 2 (continued ) 
Author, Year doi:1): (#) Study Type Original Study Title 
Funding & Sourcing 
Vaccine(s) Antibody methodology 
Measure of seropositivity 
Outcome: 
Safety 
systemic reactions (SC / IM) 
n=20/58 (34.5%) / n=24/58 (41.4%) 
SAE 
n=0/116 (0%) 
Oberle et al. [60] 2016 
doi: 10.1097/INF. 
0000000000001073 
retrospective analysis of 
German pediatric database 
ESPED13) 
Anaphylaxis after immunization of children and 
adolescents in Germany 
Funding & sourcing: 
N/A 
1 unspecified 
1 strain K23 
(probably 
Encepur®) 
N/A 2 of 22 post-immunization anaphylactic incidences in 
Germany between June 01, 2008 and May 31, 2010 
occurred after TBE-vaccination. Based on 3’125’546 
administered doses of TBE vaccine in Germany, the 
incidence was calculated at 0.69 (0.67 – 1.2) [1.0 (0.99 – 
1.4)] (Point Estimate and 95% confidence interval) per 
million TBE doses administered.14) 
Konior et al. [53] 2017 
https://doi.org/10.1016/j. 
vaccine.2017.03.059 
prospective, follow-up cohort 
study 
Seropersistence of TBE virus antibodies 10 years after first 
booster vaccination and response to a second booster 
vaccination with FSME-IMMUN 0.5 mL in adults 
Funding & sourcing:  
- Pfizer 
FSME-Immun® Neutralization Test titers 
≥1:10 
47 individuals were assessed for Safety data 
mild adverse events: (fatigue, 
injection pain, malaise) 
n=2/32 (4.3%) 
Serious adverse events: n=0/47 (0%) 




open-label, phase IV, controlled 
cohort study 
Allergic patients with and without allergen-specific 
immunotherapy mount protective immune responses to 
tick-borne encephalitis vaccination in absence of 
enhanced side effects or propagation of their Th2 bias 
Funding & sourcing:  
- Pfizer  
- UCB Pharma  
- MSD  
- Baxter  
- Sanofi 
FSME-Immun® Neutralization Test titers 
≥1:10 
119 individuals (70 allergic, 49 controls) were investigated 
for safety data. There was found no risk increase for 
exacerbations and for difference in adverse events rate of 
the allergic groups in comparison to the non-allergic 
group.15) 
local reactions: n (%) 
allergic no SIT15) group 23/49 (50%) 
males: 0/19 (0%) 
females: 23/30 (77%) 
allergic + SIT15) group 12/21 (57.1%) 
males: 5/9 (56%) 
females: 7/12 (58%) 
control group 27/49 (55.1%) 
males: 6/19 (32%) 
females: 21/30 (70%) 
systemic reactions: n (%) 
allergic groups 31/70 (44.3%) 
control group 23/49 (46.9%) 
Pöllabauer et al. [21] 2019 
https://doi.org/10.1016/j. 
vaccine.2019.03.032 
prospective, open-label, phase 
IV, 
follow-up cohort study 
Seropersistence and booster response following 
vaccination with FSME-Immun in children, adolescents, 
and young adults 




Neutralization Test titers 
≥1:10 
In 231 children assessed for adverse events, no vaccine- 
related serious adverse events or deaths were reported. 
1) Digital Object Identifier; 2) SAE = Serious adverse events; LR = Local reactions; SR = Systemic reactions; Systemic reactions were considered not to be related to the vaccination; 3) E.C. = Encepur® Children; F–I.J. =
FSME-Immun® Junior; 4) Dose-finding study of FSME-Immun® Junior; 5) Fever at 2nd dose only reported being much lower than 1st dose. Fever showed age dependency; 6) FSME-IJ = FSME-Immun® Junior; Ence. C. =
Encepur® Children; SAE = Serious adverse events; Both vaccines present well tolerance in children 1–11 years of age. A significant lower rate of injection site reaction was reported after vaccination with FSME-Immun® 
Junior compared to Encepur® Children. Close to equal were both vaccines in terms of systemic reactions and fever. Fever was reported more often in children aged 1–2 years compared to other age groups and injection site 
reaction was showing the lowest rate in this age group; 7) based on all reports received by the Swiss Federal Office of Public Health or the National Drug Pharmacovigilance Center (“Schweizerische Arzneimittelne-
benwirkungszentrale); 8) In a passive reporting system, such as the ones investigated, milder events tend to be reported at a lower rate making numbers of SAE overrepresented. Incidence of serious adverse events reported 
to be 2.3 (95%CI: 1.4–3.5) per 100′000 distributed TBE-vaccine doses. Incidence of any adverse drug reactions for any kind of vaccine was described to be 2.7 per 100′000 distributed vaccine doses; 9) AE = adverse events; 
SAE = serious adverse events; 10) 298 children assessed for adverse events within seven days of third vaccination dose. No statistically significant differences between Encepur® Children and FSME-Immun® Junior for first 
and second vaccination reported; 11) SAE = serious adverse events; SAE were considered unrelated to the study vaccine by the authors and happened during the long follow-up time. Elective surgeries were not considered 
as SAE. During the study period four deaths occurred (two grade IV glioblastomas, one myocardial infarction and one suicide). As the suicide did not receive intervention it was not included into the safety analysis, 
therefore, only three deaths are included into SAE; 12) SC = subcutaneous; IM = Intramuscularly; SAE = serious adverse events; There was a significant lower local adverse event rate of redness, swelling and local pain in 
the intramuscularly route compared to the subcutaneous; 13) ESPED – Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland (German pediatric surveillance unit); 14) Half the anaphylaxis cases following 
unspecific vaccinations occurred after the first dose. Authors conclude that either another component in the vaccine was the origin of the anaphylaxis or another molecular pathway without need of sensitization started the 
anaphylaxis; 15)SIT = specific immunotherapy; In the group with specific immunotherapy females showed an equal frequency on adverse events compared to males, whereas females in the group without specific 
immunotherapy and in the healthy control group showed higher adverse events rate than men in the same groups. 
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4.2. Safety (Table 2) 
17 original articles reported safety data. Local reactions/mild 
adverse events such as pain at the injection site, tenderness or local 
swelling were described in 24.8% (4.3–54%) of study participants [18, 
19,35,37,38,40,46,53,56,57]. Systemic reactions were reported in about 
30% (0.6–45.9%) of vaccinees [18,35,38,40,56]. Fever was reported in 
3.4% (0–9.7%) of vaccinees [18,19,35,38,40,46,47]. Systemic reactions 
were reported to be lower after the 2nd dose compared to the first dose 
administration [19]. Higher rates of local and systemic reactions were 
reported in 7–11 year old children compared to 1–2 and 3–6 year old age 
groups [18]. In adults, no age pattern of adverse events was found. 
Furthermore, the application route led to differences in adverse event 
reporting: A significantly lower local adverse event rate of redness, 
swelling and local pain in the intramuscular administration group 
compared to the subcutaneous group was reported. Systemic reactions 
were reported to be increased in the intramuscular group, however, this 
was not statistically significant [35]. 
Ten studies in our analysis comprising 4455 vaccinees reported no 
serious adverse events (SAE) [18,19,21,35,37,38,46,47,53,54]. Three 
studies described SAE: One Encepur® booster five-year follow-up study 
reported an incidence rate of 5% in 278 adults. These SAE were 
considered by the authors to be “life events” during the long follow-up 
and not related to the vaccination (including two grade IV glioblas-
tomas and one myocardial infarction), the possibility of an etiologic link 
was suggested by Strojnik in 2017 describing neurotropic viral genome 
in glioblastoma cells [40,58]. The second study reporting SAE was a 
surveillance study in a passive Swiss reporting system and it described 
19 SAE after unspecified TBE-vaccine administration, leading to a 
calculation of an incidence rate of 2.3 SAE in 100′000 distributed doses 
of vaccine [59]. The third publication, a retrospective analysis of a 
German pediatric surveillance database, presented two cases of 
anaphylactic shocks after TBE vaccination (one unspecified vaccine, one 
based on K23 – probably Encepur®). Based on TBE vaccines 
Fig. 1. Prisma flow diagram.  
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administration numbers in Germany, the incidence was calculated at 
0.69 (0.67–1.2) [1.0 (0.99–1.4)] (Point Estimate and 95% confidence 
interval) per million TBE-doses administered [60]. 
Based on the data it wasn’t possible to identify sex patterns of 
adverse events. Although one paper showed adverse events to be re-
ported at a higher rate in healthy females and in allergic females without 
specific immunotherapy compared to healthy men and allergic men 
without specific immunotherapy [56]. Further data about safety is dis-
played in Table 2. 
4.3. Research abstracts and case reports/series 
4.3.1. Immunogenicity and safety data 
Four research abstracts of poster-/oral sessions and one case series 
reported data on immunogenicity in thymectomized children (presented 
in 2009) or juvenile idiopathic arthritis (JIA) patients (presented in 
2015) [61,62]. An adequate response was achieved in these groups after 
full vaccination. In a cohort study of 33 adults a lower antibody response 
was found in individuals aged 60–80 years compared to age group 
21–31 years (presented in 2012) [63]. Another controlled cohort study 
demonstrated an adequate protective antibody level after primary TBE 
vaccination in elderly [64]. One case-series described four reported 
vaccine failures: one patient was deemed not to be a vaccine failure case 
(no second booster vaccination), two individuals to be probable vaccine 
failures and one case to be a confirmed vaccine failure [24]. 
Three case reports and one case series reported safety data. Jiménez 
et al. described the use of a statistical measure, the Information Com-
pound (IC) measure of association. An IC score of 3.0 was found for TBE 
vaccines suggesting a statistical association between TBE vaccine and 
facial paralysis, compared to an IC score of 3.1 for a H1N1 influenza 
pandemic vaccine, an IC score of 3.0 for a hepatitis b/a vaccine or an IC 
score of 2.3 for a yellow fever vaccine [65]. Another case report 
described the reactivation of immune thrombocytopenic purpura by a 
TBE vaccination (FSME-Immun®) with subsequent recovery [66]. A 
3-case series investigated excessive daytime sleepiness and 
narcolepsy-cataplexy starting a few weeks, one month, and two months 
after TBE vaccination (vaccine unspecified) [67]. In an expert opinion 
forum, a case of a 2 year old-child with facial paralysis presenting two 
days after second TBE dose was considered to be unrelated to the 
TBE-vaccination [68]. 
5. Discussion 
Our systematic review found TBE vaccines Encepur® and FSME- 
Immun® to be highly immunogenic, well tolerated and in all studies 
except one to be interchangeable. There were some conflicting results 
with regard to age at first vaccination and booster intervals and the 
timing of vaccine administration and the use of accelerated schedules 
(Table 3). The immunogenicity of these vaccines has been shown to be 
adequate after primary vaccination and following booster doses in all 
age groups. The duration of seropositivity in individuals aged ≥50 years 
was reduced and studies point to reduced long-term protection in older 
Table 3 
Primary vaccination schedules and immunogenicity.  
Author Seropositivityb 
Years after TDa 
Loew-Baselli et al. [38]  
3 years after TD with F&Ec  
Age group 18-50 97.1% 
Age group 51-67 87.3% 
Prymula et al. [18]  
28 days after TDa with  
2x Ence. C.d + 1x FSME-I. J.®e 100% 
3x FSME-Immun® Junior 100% 
Beran et al. [40]  
5 years after TDa with Encepur®  
Conventional schedulef 100% 
Rapid schedulef 100% 
Accelerated schedulef 99% 
Aerssens et al. [57]  
≥8 years after TDa with FSME-I. J.®e J  
age range 8–17 yearsg 51% 
Dorko et al. [39]  
8 monthsh after TDa with FSME-I. J.®e 90.9% 
Pöllabauer et al. [21]  
4 years after TDa with FSME-I. J.®e  
total (age 1–15 years) 93.7% 
5 years after TDa with FSME-I. J.®e  
total (age 1–15 years) 84.9% 
age group 1-2 84.9% 
age group 3-6 95.6% 
age group 7-11 85.7% 
age group 12-15 73.7%  
a TD = third dose. 
b Seropositivity = NT titers ≥ 1:10. 
c F&E = FSME-Immun® and Encepur®. 
d Ence C. = Encepur® Children. 
e FSME I.J. = FSME-Immun® Junior. 
f Demonstrated in per-protocol set, whereas in all-screened set at five-year 
follow-up: conventional schedule = 94%, rapid schedule = 90%, accelerated 
schedule = 93%. 
g Demonstrated in 69 patients. 
h Median with a range of 0.5–34 months. 
Table 4 










for start of 
vaccination 
6 yearsa no specific 
ageb 
1 year Depending 






Primary schedule in 
months 
3 doses 3 doses 3 doses 3 doses <50 
years 
4 doses >50 
years 






0, 1–3, 5–12 
after 2nd 






0, 1–3, 5–12 
after 2nd 





FSME-Immun® 0, 14 days, 
5–12 
monthsc 








Encepur® 0, 7, 21 daysc 0, 7, 21 
days 
0, 7, 21 
days 
N/Ad 
First booster interval 
primary schedulee 10 years 3 years 3 years 3 years 





2nd and following Booster intervals: 
<50 years 10 years 5 years 5 years 5 years 
50–59 years 10 years 3 years 5 years 5 years 
≥60 years 10 years 3 years 3 years 5 years  
a Below six years individual risk-benefit estimation. 
b Individuals below 3 years of age should be taken into consideration. 
c Swiss government vaccine advice documents only described rapid schedules 
as being available. Exact timing was taken according to the manufacturer’s 
package insert. 
d Rapid schedule described as available but not to prefer if possible. 
e After regular primary schedule or after primary rapid schedule with the 
vaccine Encepur® used. 
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adults. In terms of safety, the European, licensed vaccines were found to 
be well tolerated in both children (aged 1–17 years) and in adults, with 
local injection site reactions in 24.8% (4.3–54%) and systematic re-
actions in 30% (0.6–45.9%) of vaccinees. Vaccine related serious 
adverse events (SAE) were rare. 
The conventional TBE vaccination schedule (0,28, 300 days) was 
superior to other schedules in the short-term only [31,46]. Studies show 
that long-term immunogenicity, after several booster vaccinations, was 
comparable regardless of the primary vaccination schedule [29,40]. 
Nevertheless, rapid vaccination schedules should be administered only 
in individuals requiring protection within a short timespan (such as 
travellers). 
The interchangeability of the two European vaccines was shown in 
several publications except one from Wittermann et al. which showed a 
faster decline of antibody levels after a mixed primary vaccination 
schedule [16,18,37,38,46]. It appears that a mixed vaccine approach 
can be considered but is not optimal. 
Many countries consider that the primary vaccination schedule 
protects for at least 3 years (Austria, Germany, Sweden), whereas in 
Switzerland the recommended first booster dose is ten years after the 
primary schedule [69]. The evidence from this systematic review sup-
ports an earlier first booster dose at 3–5 years in children and adults [16, 
21,51,52,70]. 
Subsequent booster intervals of at least 5 years in healthy adults were 
recommended in five studies and indeed, adequate post-booster pro-
tection from 5 years up to ten years for adults and/or children was 
confirmed [2,10,21,37,40,50]. Our results show a safe immunogenicity 
of TBE-vaccines for up to ten years after booster vaccination in healthy 
children (seropositivity at ten year follow-up: 90.3%) and adults below 
60 years (seropositivity at ten year follow-up: 77.3%–94%) although 
lower immunogenicity was observed in adults > 50 years of age. Older 
individuals who have had a 4-dose primary schedule show longer 
duration of seropositivity after booster doses [2]. Therefore, to ensure 
protection of older people, recommendations should include a fourth 
vaccination during the primary schedule and shorter booster intervals 
[2,22,54]. 
Evidence on immunogenicity and safety of TBE vaccination in special 
risk groups remains scant. In a cohort of 70 allergic individuals an im-
mune response after TBE-vaccination was comparable to healthy con-
trols [56]. In studies with limited numbers, immunosuppressed patients 
showed a lower immune response compared to healthy individuals [54, 
71]. For thymectomized individuals the evidence shows only an early 
decreased immune response later approaching levels comparable to 
healthy controls [55,61]. Immunosuppressed groups must be informed 
of their high-risk status and should receive an extra dose of TBE-vaccine 
for primary vaccination regardless of age. There are research gaps: We 
found no studies documenting incidental TBE vaccine use in pregnant or 
breastfeeding women. There are few data on use of the vaccine in dia-
betic patients. Study results were rarely stratified by age and sex, 
although there are some indications that this is important. 
TBE vaccines have both shown to be well tolerated in children and 
adults with a lower rate of injection site reactions reported with FSME- 
Immun® Junior compared to Encepur® Children [17–19]. In 10 out of 
13 investigated studies analyzing SAE in 4455 individuals no SAE were 
recorded [18,19,21,35,37,38,46,47,53,54]. In a 5-year follow up study, 
an incidence rate of 5% SAE was reported for 313 investigated in-
dividuals. These SAE were considered “life events” unrelated to the 
vaccine [40]. In a Swiss surveillance study of 73 adverse events in the 
years 1991–2001 following TBE-vaccination 19 presented to be SAE 
corresponding to a rate of 2.3 SAE per 100,000 distributed doses. This 
time span includes the application of the old mouse-brain derived TBE 
vaccines [59]. Another study of a German pediatric surveillance data-
base described anaphylactic shock after TBE-vaccination and showed an 
SAE incidence of 0.69 (0.67–1.2) [1.0 (0.99–1.4)] per million TBE doses 
administered [60]. In summary, SAE associated with TBE vaccination 
are rare. 
The issue of the timing and the frequency of booster doses is 
important: Swiss vaccine recommendations, issued by the Federal Office 
of Public Health, recommend administration of TBE-vaccine to all 
healthy individuals (>6 years old) in all areas except the cantons of 
Geneva and Ticino. The primary vaccination schedule should be 
administered, depending on the vaccine used, at months 0, 1 and 5–12. 
Thereafter booster vaccinations are recommended every 10 years in all 
age groups [8]. Swiss recommendations for booster vaccines differ from 
other countries’ guidelines where boosters are recommended at earlier 
intervals [72–74] (Table 4). 
Vaccination coverage of TBE vaccination is not actively monitored in 
Switzerland and therefore it is not possible to describe actual coverage, 
amount of used vaccines or field effectiveness of TBE-vaccines in the 
Swiss population. An unpublished report suggests a national TBE 
vaccination coverage of 9.5% for four TBE doses (personal communi-
cation Vasiliki B). In Austria Heinz et al. described a field effectiveness 
for regularly TBE-vaccinated individuals estimated to be around 99% 
under best case scenario and 96% under worst-case assumptions [34]. 
To increase coverage, Switzerland’s rules for vaccination availability 
were adapted in 2015: certain cantons allowed community pharmacists 
with vaccination certification to administer specific vaccines, such as 
TBE-vaccine without prescription [75]. To expand coverage of 
TBE-vaccine, the Swiss army recommended voluntary TBE-vaccinations 
in young recruits, since 2007 [76]. Because service is only mandatory for 
Swiss men, there needs to be found another way to reach Swiss females 
and those who are not of Swiss nationality. 
A strength of this Systematic Review is that it was conducted in 
accordance with PRISMA guidelines [28]. Five online databases were 
searched to include all the important publications and to summarize 
most important evidence for the European TBE-vaccines and the main 
results are highlighted in Table 5. Limitations of this systematic review 
were the different approaches of the included and investigated studies 
making outcomes hard to compare. Per example different laboratory 
tests used like Enzyme-linked Immunosorbent Assay (ELISA) and NT 
may not always be comparable. With regard to capturing SAE, most of 
the vaccine studies investigated, had a small sample size and were not 
powered to detect rare or SAE. Surveillance systems did identify SAE 
Table 5 
Main findings from the systematic review.  
Elderly >60 years 
Immunosenescence [9,22,44,70] 
Diminishing immune system starting at 50–60 years 
Booster Interval [53,70] 
Adequate immunogenicity up to three years after a TBE vaccine dose 
Recommendation: Booster doses (≥4 doses) every three years for >60 years 
Children 1–15 years [19,38,46,47] 
Well tolerated and safe vaccination with Encepur® Children andFSME-Immun® 
Junior 
First Booster dose timing <50 years 
Encepur® & FSME-Immun® [21,40] 
Adequate protectivity five years after last dose of primary vaccination 
Recommendation: First booster dose five years after primary vaccination 
Subsequent Booster intervals <50 years 
Encepur® & FSME-Immun® [10,52,53] 
Adequate protectivity ten years after first booster (fourth dose) vaccination 
Recommendation: Subsequent booster intervals every ten year 
Booster intervals 50–60 years 
Encepur® & FSME-Immun® [9,53] 
Lower immune response and faster decrease of protective antibody levels 
Recommendation: Early transition from ten- to two-year booster intervals 
Interchangeability of Encepur® and FSME-Immun® 
Interchangeable [18,37,38,46] 
Adequate Immunogenicity after mixed vaccine administration 
Diminished protectivity [16] 
Faster decrease of protective antibodies following mixed primaryvaccination 
schedule 
Recommendation: Use of mixed vaccination only in exception and with ad- 
ministration of earlier subsequent booster vaccination.  
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reports. Many of the key studies were conducted directly or funded by 
TBE vaccine manufacturers. Future surveillance systems need to be 
strengthened to enable detection of very rare adverse events as well as 
TBE cases to allow finetuning of risk assessment. Additionally, more 
research must be done on sex differences in TBE vaccine response and 
booster intervals for individuals 50–59 years of age, impact of age at 
priming and on vaccine response in the immunocompromised. To 
further evaluate TBE vaccine recommendations, it is essential to 
continuously follow up all previously vaccinated TBE cases with respect 
to the number of doses and the time of vaccination. This information 
should be collated in a vaccination register to avoid memory or 
reporting biases. 
In conclusion, TBE vaccination is generally safe with rare serious 
adverse events. Schedules should, if possible, use the same vaccine 
brand (non-mixed) and be age adjusted. TBE vaccines are immunogenic 
in terms of antibody response but less so when vaccination is started 
later than the age of 50 years. Age at priming is a key factor in the 
duration of protection. 
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Detailed search strategy and keywords in the five databases CINAHL, Cochrane, Embase, PubMed, and Scopus  
Search 
Step 
CINAHL Cochrane Embase PubMed Scopus1) 
1 tick borne disease tick-borne ‘tick borne Encephalitis, Tick-Borne2) tick AND borne AND 
encephalitis encephalitis encephalitis’/exp 
2 encephalitis, tick borne Publication 
Year >
‘tick borne Encephalitis3) tick-borne AND 
encephalitis 
2009 encephalitis’ 
3 tick-borne encephalitis Date added to 
database 




4 encephalitis, tick-borne 1 AND 2 AND 3 ‘fsme’ tick-borne encephalitis3) 1 OR 2 OR 3 
5 fsme  Combine 1–4 with OR tick borne encephalitis3) adjuvant 
6 Combine 1–4 with OR  ‘adjuvant’ Fsme3) adverse AND reactions 
7 adjuvant  ‘adverse’ AND (‘reactions’ OR ‘events’) Combine 1–6 with OR side AND effects 
8 adverse (reactions AND events)  ‘side’ AND ‘effects’ Viral Vaccines2) adverse AND events 
9 side AND effects  ‘pediatric’ Drug-Related Side gender AND effects 
Effects and Adverse 
Reaction2) 
10 gender AND effects  ‘child’ OR ‘children’ Adjuvant3) gender 
11 pediatric  ‘elderly’ adverse AND (reactions OR 
events)3) 
Pediatric OR Child OR 
children 
12 child OR children  ‘immunosenescence’ side AND effects3) Elderly 
13 Elderly  ‘gender’ side AND effect3) immunocompromised 
14 immunosenescence  ‘sex’ gender AND effect3) sex 
15 gender OR sex  ‘immunocompromised’ Pediatric3) viral AND vaccines 
16 immunocompromised  ‘viral’ AND (‘vaccines’ OR ‘vaccination’) child or children3) viral AND vaccination 
17 viral AND (vaccines OR 
vaccination)  
‘virus’ AND (‘vaccines’ OR 
‘vaccination’) 
immunocompromised3) virus AND vaccines 
18 virus AND (vaccines OR 
vaccination)  
‘protect’ OR ‘protection’ Elderly3) virus AND vaccination 
19 safety AND (vaccines OR 
vaccination)  
‘dosage’ OR ‘dose’ immunosenescence3) immunosenescence 
20 protect OR protection  Combine 6–19 gender OR sex3) vaccines AND safety 
with OR 
21 dosage OR dose  Publication Year protect OR protection3) protect OR protection 
2009–20,194) 
22 Combine 7–21 with OR  Date added to database between 
January 01, 2009 and 31/08/20,196) 
viral AND (vaccines OR 
vaccination)3) 
vaccination AND safety 
23 Publication time between January 
2009 and August 2019  
5 AND 20 AND 21 AND 22 virus AND (vaccines and 
vaccination)3) 
dosage OR dose 
24 6 AND 22 AND 23   safety AND (vaccine OR 
vaccination)3) 
Combine 5–23 with OR 
25    dosage OR dose3) Publication Year 
2009–20,197) 
26    Combine 8–25 with OR 4 AND 24 AND 25 
27    Publication Date5) January 01, 
2009–August 31, 2019  
28    7 AND 26 AND 27  
1) Search-type for Scopus: Title-Abs-Key (…);2) Search type: “ …“ [Mesh];3) Search type “ …“ [All Fields];4) Original search: (2009:py OR 2010:py OR 2011:py OR 2012: 
py OR 2013:py OR 2014:py OR 2015:py OR 2016:py OR 2017:py OR 2018:py OR 2019:py);5) (“2009/01/01"[PDAT]: “2019/08/31"[PDAT]);6) [1-1-2009]/sd NOT 
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[1–9]/sd;7) (LIMIT-TO(PUBYEAR, 2014) OR LIMIT-TO(PUBYEAR, 2013) OR LIMIT-TO(PUBYEAR, 2012) OR LIMIT-TO(PUBYEAR, 2019) OR LIMIT-TO(PUBYEAR, 
2018) OR LIMIT-TO(PUBYEAR, 2017) OR LIMIT-TO(PUBYEAR, 2016) OR LIMIT-TO(PUBYEAR, 2015) OR LIMIT-TO(PUBYEAR, 2011) OR LIMIT-TO(PUBYEAR, 
2010) OR LIMIT-TO(PUBYEAR, 2009).  
Appendix 2 
Strength of original research assessment table  
Author, Year Randomized Concealed 
allocation 
Controlled Blinding Inclusion of >90% 
patients in analysis 
Dropouts described comments 
Jílková NO – YES open-label NO Adequate 1/3 of study population in rapid 
schedule excluded [79] 2009 (75.5% included in 
final analysis) 
Loew-Baselli NO – YES open-label Immun: NO (60.7% 
at 3yfu1)) 
appropriate only from 
follow-up time point  [38] 2009 
Paulke- 
Korinek 
NO – NO open-label Immun: YES Adequate  
[44] 2009 
Plentz NO – NO open-label Immun: YES Adequate  
[51] 2009 
Stiasny NO – YES N/A YES No dropouts retrospective analysis of vaccine failures 
[41] 2009 
Wittermann YES – YES single-blind Immun.: YES No dropouts  
[20] 2009 Safety: YES 
Wittermann NO – NO open-label NO Adequate  
[50] 2009 (81.9% at 5yfu1)) 








IMMUN: YES Numbers provided – 
reasons not described  







Pöllabauer YES N/A YES single-blind YES Yes  
[19] 2010 
Schumacher NO – NO – YES N/A retrospective safety data analysis 
[59] 2010 
Weinberger NO – YES N/A YES NO  
[9] 2010 
Zlamy NO – YES open-label N/A N/A  
[55] 2010 
Mad’ar NO – NO open-label YES N/A retrospective data analysis 
[82] 2011 
Orlinger NO – NO – YES N/A  
[4] 2011 
Askling NO – NO open-label NO YES 313 included, 53 lost to follow-up 
[37] 2012 (83% included) 
Baldovin NO – YES N/A YES No dropouts  
[70] 2012 




NO – YES N/A YES N/A  
[1] 2013 
Heinz – – – – YES N/A vaccination coverage and TBE incidence 
study [34] 2013 
Paulke- 
Korinek 
NO – NO open-label NO appropriate follow up study 
[22] 2013 (42.6% at 10yfu1)) 
Beran NO – YES NO Immun: YES appropriate Follow-up Study 
[40] 2014 Safety: NO (78% 
included) 
Lindblom NO – NO N/A YES No dropouts  
[80] 2014 
Remoli No – YES open-label YES N/A  
[81] 2014 
Schosser NO – NO open-label NO appropriate 2915 enrolled subjects and 1240 
(42.6%) included for analysis [36] 2014 (42.6% included) 
Schuler NO – NO open-label N/A N/A Surveillance study 
[43] 2014 
Wittermann NO – YES open-label After 3 years group of 
111 discontinued 
appropriate follow-up study 
[16] 2015 
Aerssens NO – NO open-label YES No dropouts  
[57] 2016 
Beck YES Unknown YES Unknown YES No Dropouts All tested sera included into analysis 
[48] 2016 
Beškovnik NO – NO N/A YES appropriate  
[52] 2016 
Hertzell NO – YES open-label YES No Dropouts  
(continued on next page) 
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Appendix 2 (continued ) 
Author, Year Randomized Concealed 
allocation 
Controlled Blinding Inclusion of >90% 
patients in analysis 
Dropouts described comments 
[54] 2016 
Hopf YES N/A YES N/A YES No Dropouts  
[35] 2016 
Oberle NO – NO – N/A N/A surveillance study 
[60] 2016 
Konior NO – NO open-label YES appropriate  
[53] 2017 
Lotrič-Furlan NO – YES open-label YES No Dropouts TBE-breakthrough data analysis (no 
intervention) [42] 2017 




No – YES open-label YES No Dropouts  
[56] 2018 
Beran NO – YES open-label NO appropriate  
[10] 2019 (51.5% at 10yfu1)) 
Hansson NO – NO open-label YES No dropouts retrospective database analysis 
[2] 2019 
Pöllabauer NO – NO open-label NO appropriate 179 enrolled into 10yfu from 205 
receiving 2nd booster dose (87%) and 
358 from earlier study 
[21] 2019 (87% at 10yfu1))  
1) yfu = years of follow-up. 
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[21] Pöllabauer E, Angermayr R, Behre U, Zhang P, Harper L, Schmitt H, et al. 
Seropersistence and booster response following vaccination with FSME-IMMUN in 
children, adolescents, and young adults. Vaccine 2019;37:3241–50. https://doi. 
org/10.1016/j.vaccine.2019.03.032. 
[22] Paulke-Korinek M, Kundi M, Laaber B, Brodtraeger N, Seidl-Friedrich C, 
Wiedermann U, et al. Factors associated with seroimmunity against tick borne 
encephalitis virus 10 years after booster vaccination. Vaccine 2013;31:1293–7. 
https://doi.org/10.1016/j.vaccine.2012.12.075. 
[23] Heinz FX, Holzmann H, Essl A, Kundi M. Field effectiveness of vaccination against 
tick-borne encephalitis. Vaccine 2007;25:7559–67. https://doi.org/10.1016/j. 
vaccine.2007.08.024. 
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et al. Vaccination of patients with diabetes mellitus - a retrospective study. Cent 
Eur J Publ Health 2011;19:98–101. https://doi.org/10.21101/cejph.a3634. 
[83] Swiss vaccination schedules. Fed off Public Heal n.d. https://www.bag.admin.ch/ 
bag/de/home/gesund-leben/gesundheitsfoerderung-und-praevention/impfungen 
-prophylaxe/schweizerischer-impfplan.html (accessed December 16, 2019). 
J.E. Rampa et al.                                                                                                                                                                                                                               
